Family history of colorectal cancer in BRAF p.V600emutated colorectal cancer cases

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 5, 2013, Pages 917-926

  Buchanan, Daniel D ^a   Win, Aung K ^d   Walsh, Michael D ^a   Walters, Rhiannon J ^a   Clendenning, Mark ^a   Nagler, Belinda ^a   Pearson, Sally Ann ^a   Macrae, Finlay A ^f   Parry, Susan ^g,h   Arnold, Julie ^h   Winship, Ingrid ^d,f   Giles, Graham G ^e   Lindor, Noralane M ^j   Potter, John D ^i,k   Hopper, John L ^d   Rosty, Christophe ^a,b,c   Young, Joanne P ^a,c   Jenkins, Mark A ^d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Envoi Pathology ^*  (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g Department of Rheumatology   (Australia)

^h New Zealand Familial Gastrointestinal Cancer Service   (New Zealand)

ⁱ MASSEY UNIVERSITY   (New Zealand)

^j MAYO CLINIC   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; ARTICLE; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; FAMILY HEALTH; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84877931368     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1211     Document Type: Article

References (44)

1. WHO. Cancer incidence in five continents. Lyon, France: The World Health Organization and The International Agency for Research on Cancer; 2002.
2. Burt RW, Bishop DT, Lynch HT, Rozen P, Winawer SJ. Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1990;68:655-65.
3. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
4. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007;21:2525-38.
5. Aaltonen L, Johns L, Jarvinen H, Mecklin JP, Houlston R. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 2007;13: 356-61.
6. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004;53:1137-44.
7. Jass Jr. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-30.
8. Jass Jr. Serrated route to colorectal cancer: Back street or super highway? J Pathol 2001;193:283-5.
9. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93.
10. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: A literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012;49:151-7.
11. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
12. Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 2012;55:128-33.
13. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: An aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012;36:744-52.
14. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
15. Roberts A, Nancarrow D, Clendenning M, Buchanan DD, Jenkins MA, Duggan D, et al. Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome). Fam Cancer 2011;10: 245-54.
16. Young J, Barker MA, Simms LA, Walsh MD, Biden KG, Buchanan D, et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005;3:254-63.
17. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, Gattas M, et al. Phenotypic diversity in patients with multiple serrated polyps: A genetics clinic study. Int J Colorectal Dis 2010;25:703-12.
18. Wish TA, Hyde AJ, Parfrey PS, Green JS, Younghusband HB, Simms MI, et al. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: A population-based study. Cancer Epidemiol Biomarkers Prev 2010;19: 1831-9.
19. Vandrovcova J, Lagerstedt-Robinsson K, Pahlman L, Lindblom A. Somatic BRAF-V600E mutations in familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2270-3.
20. Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: A constellation approach. Gastroenterology 2010;138:877-85.
21. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: An international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2331-43.
22. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al., editors. International classification of diseases for oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
23. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043-8.
24. Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population-and clinicbased colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 2011;13:271-81.
25. Walsh MD, Buchanan DD, Pearson SA, Clendenning M, Jenkins MA, Win AK, et al. Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: A case series from the Australasian site of the colon cancer family registry. Mod Pathol 2012;25:722-30.
26. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
27. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008;17:3208-15.
28. Clendenning M, Hampel H, LaJeunesse J, Lindblom A, Lockman J, Nilbert M, et al. Long-range PCR facilitates the identification of PMS2-specific mutations. Hum Mutat 2006;27:490-5.
29. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-linePMS2 mutations. Gastroenterology 2008;135:419-28.
30. Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, et al. Lynch syndrome-associated breast cancers: Clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 2010;16:2214-24.
31. Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline MutY human homologue mutations and colorectal cancer: A multisite case-control study. Gastroenterology 2009;136: 1251-60.
32. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, English DR, et al. Risk factors for colorectal cancer in patients with multiple serrated polyps: A cross-sectional case series from genetics clinics. PLoS ONE 2010;5:e11636.
33. Loughrey MB, Waring PM, Tan A, Trivett M, Kovalenko S, Beshay V, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007;6:301-10.
34. Young J, Jass Jr. The case for a genetic predisposition to serrated neoplasia in the colorectum: Hypothesis and review of the literature. Cancer Epidemiol Biomarkers Prev 2006;15:1778-84.
35. Levine AJ, Win AK, Buchanan DD, Jenkins MA, Baron JA, Young JP, et al. Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: Data from the colorectal cancer family registry. Cancer Prev Res 2012;5:328-35.
36. McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh MD, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSIH colon cancer. Fam Cancer 2004;3:101-7.
37. Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A,Morikawa T, et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 2013;105:130-40.
38. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010;9:125.
39. Goel A, Xicola RM, Nguyen TP, Doyle BJ, Sohn VR, Bandipalliam P, et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2010; 138:1854-62.
40. Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS ONE 2012;7:e45357.
41. Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-73.
42. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
43. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al.CpGisland methylator phenotype, microsatellite instability,BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
44. Lubomierski N, Plotz G, WormekM, Engels K, Kriener S, Trojan J, et al. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 2005;104:952-61.